July 31, 2026

To, **National Stock Exchange of India Limited**, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai – 400 051	To, **BSE Limited**, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	**Scrip Code: 532296**
ISIN: INE935A01035	**ISIN: INE935A01035**
Our Reference No. 35/26-27	**Our Reference No. 35/26-27**

Dear Sir/ Madam,

Sub: Outcome of Board Meeting for the quarter ended June 30, 2026 - SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**Listing Regulations**"), we wish to inform that the Board at its meeting held today, i.e. July 31, 2026 has approved the following:

A. Financial Results

1. The Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026; and
2. Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.

B. Annual General Meeting ("AGM") and Record Date

1. The 48th (Forty - Eighth) AGM of the members of the Company will be held on **Friday, September 11, 2026**, at 2:00 P.M. at Mumbai through video-conferencing / other audio-visual means;
2. The proceedings of the AGM shall be deemed to be conducted at the Corporate Office of the Company, i.e. at Glenmark House, B D Sawant Marg, Off Western Express Highway, Andheri (E), Mumbai 400 099; and
3. The record date for the purpose of determining the entitlement of dividend for the AGM to be held for the Financial Year ended March 31, 2026 shall be **Monday, August 31, 2026**.

C. Amendments to Policies

The Board of Directors on the recommendation of respective Committees considered and approved the amendments/review of the following policies:

a. Policy on Related Party Transactions and its Materiality
b. Policy on Determination of Materiality for Disclosures
c. Insider Trading Policy
d. Dividend Distribution Policy
e. Nomination and Remuneration Policy

The revised policies shall be uploaded on the website of the Company.

D. Reconstitution of Risk Management Committee

The Board has approved the reconstitution of the Risk Management Committee with effect from August 01, 2026, where Ms. Patricia Andrews has been appointed as the Chairperson and Mr. Glenn Saldanha, Mr. Anurag Mantri and Mr. Dipankar Bhattacharjee will be the Members of the Committee.

The Board Meeting commenced at 04.00 p.m. and concluded at 06:20 p.m.

This intimation will also be uploaded on the Company's website at www.glenmarkpharma.com and the extract of the aforesaid results would be published in the newspapers in accordance with the Listing Regulations.

You are requested to take the same on records.

Thanking You.

Yours faithfully,
Rashmi Khandelwal

Rashmi Khandelwal
Digitally signed by Rashmi Khandelwal
Date: 2026.07.31 18:31:09 +05'30'

Company Secretary & Compliance Officer
ACS – 28839

Encl: As above

glenmark
A new way for a new world

Glenmark Pharmaceuticals Limited
Statement of Unaudited financial results for the quarter ended 30 June 2026
(All amounts in million of Indian Rupees, unless otherwise stated)

	Particulars	Standalone			
		Quarter ended 30/06/2026 (Unaudited)	Quarter ended 31/03/2026 (Refer note 9)	Quarter ended 30/06/2025 (Unaudited)	Year ended 31/03/2026 (Audited)
I	Revenue from operations				
	(a) Net sales	23,425.26	22,075.64	21,788.96	79,342.23
	(b) Other operating income	924.67	(609.88)	2,160.32	5,058.76
	Total revenue from operations	24,349.93	21,465.76	23,949.28	84,400.99
II	Other income	1,154.11	3,078.76	693.35	7,720.23
III	Total income (I + II)	25,504.04	24,544.52	24,642.63	92,121.22
IV	Expenses				
	(a) Cost of materials consumed	6,279.86	7,209.20	6,772.40	27,755.75
	(b) Purchases of stock-in-trade	1,414.36	1,135.01	993.25	4,087.95
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	491.60	(9.29)	(584.10)	(1,054.15)
	(d) Employee benefits expense	4,540.81	4,613.45	4,084.43	17,904.10
	(e) Finance costs	232.45	179.12	154.58	787.45
	(f) Depreciation, amortisation and impairment expense	623.17	601.33	576.39	2,358.89
	(g) Other expenses	5,490.77	8,202.08	5,401.71	24,933.36
	Total expenses (IV)	19,073.02	21,930.90	17,398.66	76,773.35
V	Profit/(loss) before exceptional items and tax (III - IV)	6,431.02	2,613.62	7,243.97	15,347.87
VI	Exceptional items (gain)/ loss (Refer note 5)	(2,230.00)	3,687.59	3,232.32	18,008.58
VII	Profit/(loss) before tax (V - VI)	8,661.02	(1,073.97)	4,011.65	(2,660.71)
VIII	Tax expense :				
	Current tax	1,128.41	-	701.72	-
	Deferred tax	176.24	(334.95)	7.67	(652.72)
IX	Profit/(loss) after tax for the period / year (VII - VIII)	7,356.37	(739.02)	3,302.26	(2,007.99)
X	Profit/(loss) for the period / year attributable to:				
	- Non-controlling interests	-	-	-	-
	- Owners of the Company	7,356.37	(739.02)	3,302.26	(2,007.99)
XI	Other comprehensive income / (loss)				
	A (i) Items that will not be reclassified to profit or loss	8.10	(10.51)	(8.20)	(159.85)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(2.04)	(26.95)	2.86	(9.71)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income/(loss) for the period/ year	6.06	(37.46)	(5.34)	(169.56)
XII	Total comprehensive income for the period/ year (IX + XI)	7,362.43	(776.48)	3,296.92	(2,177.55)
XIII	Total comprehensive income attributable to:				
	- Non-controlling interests	-	-	-	-
	- Owners of the Company	7,362.43	(776.48)	3,296.92	(2,177.55)
XIV	Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.20	282.20	282.20	282.20
XV	Other equity (other than revaluation reserve)				2,41,221.04
XVI	Earnings per share (EPS) (not annualised except for the year ended 31 March)				
	Basic (in Rupees)	26.07	(2.62)	11.70	(7.12)
	Diluted (in Rupees)	26.06	(2.62)	11.70	(7.12)

WALKER CHANDIOK & CO LLP MUMBAI

GLENMARK PHARMACEUTICALS LTD. MUMBAI

glenmark

A new way for a new world

Glenmark Pharmaceuticals Limited

Statement of Unaudited financial results for the quarter ended 30 June 2026

(All amounts in million of Indian Rupees, unless otherwise stated)

	Particulars	Consolidated			
		Quarter ended Quarter ended Quarter ended	Quarter ended 31/03/2026 (Refer note 9)	Quarter ended 30/06/2025 (Unaudited)	Year ended 31/03/2026 (Audited)
I	Revenue from operations				
	(a) Net sales	39,317.30	37,602.77	30,593.33	1,67,114.03
	(b) Other operating income	867.53	103.09	2,051.07	2,711.08
	Total revenue from operations	40,184.83	37,705.86	32,644.40	1,69,825.11
II	Other income	657.64	1,890.83	264.42	4,606.19
III	Total income (I + II)	40,842.47	39,596.69	32,908.82	1,74,431.30
IV	Expenses				
	(a) Cost of materials consumed	6,010.66	7,311.96	7,324.68	29,614.59
	(b) Purchases of stock-in-trade	6,607.53	4,462.93	5,813.41	23,966.43
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(160.20)	(52.09)	(2,982.33)	(6,106.39)
	(d) Employee benefits expense	9,346.95	8,874.41	7,627.54	35,778.53
	(e) Finance costs	539.97	426.04	582.26	2,087.25
	(f) Depreciation, amortisation and impairment expense	1,731.74	1,479.09	1,299.26	5,734.81
	(g) Other expenses	10,331.93	9,482.68	9,055.90	40,847.78
	Total expenses (IV)	34,408.58	31,985.02	28,720.72	1,31,923.00
V	Profit/(loss) before exceptional items and tax (III - IV)	6,433.89	7,611.67	4,188.10	42,508.30
VI	Exceptional items (gain)/ loss (Refer note 5)	-	3,733.99	3,232.32	22,660.84
VII	Profit/(loss) before tax (V - VI)	6,433.89	3,877.68	955.78	19,847.46
VIII	Tax expense :				
	Current tax	2,108.17	(301.42)	1,093.11	6,764.86
	Deferred tax	(502.56)	1,165.91	(607.06)	(536.92)
IX	Profit/(loss) after tax for the period / year (VII - VIII)	4,828.28	3,013.19	469.73	13,619.52
X	Profit/(loss) for the period / year attributable to:				
	- Non-controlling interests	(0.96)	(0.95)	1.02	1.01
	- Owners of the Company	4,829.24	3,014.14	468.71	13,618.51
XI	Other comprehensive income / (loss)				
	A (i) Items that will not be reclassified to profit or loss	7.43	46.31	8.64	(93.85)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(2.12)	(36.31)	(1.83)	(23.59)
	B (i) Items that will be reclassified to profit or loss	450.17	2,146.84	1,017.60	4,831.97
	(ii) Income tax relating to items that will be reclassified to profit or loss	(51.00)	(270.64)	(11.29)	(570.93)
	Total other comprehensive income/(loss) for the period/ year	404.48	1,886.19	1,013.12	4,143.60
XII	Total comprehensive income for the period/ year (IX + XI)	5,232.76	4,899.39	1,482.85	17,763.12
XIII	Total comprehensive income attributable to:				
	- Non-controlling interests	(0.90)	(1.05)	0.87	0.55
	- Owners of the Company	5,233.66	4,900.44	1,481.98	17,762.56
XIV	Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.20	282.20	282.20	282.20
XV	Other equity (other than revaluation reserve)				1,04,838.89
XVI	Earnings per share (EPS)				
	(not annualised except for the year ended 31 March)				
	Basic (in Rupees)	17.11	10.68	1.66	48.26
	Diluted (in Rupees)	17.11	10.68	1.66	48.24

WALKER CHANDIOK & CO LLP MUMBAI

GLENMARK PHARMACEUTICALS LTD. MUMBAI

Glenmark Pharmaceuticals Limited
Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India
T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No. L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

glenmark
A new way for a new world

Notes:

1. The Financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34, Interim financial reporting ('Ind AS 34') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued from time to time.

2. The above financial results were reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on 31 July, 2026. These results have been subjected to limited review by statutory auditors who have expressed an unmodified review conclusion.

3. The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.

4. As at 30 June, 2026, pursuant to Employee Stock Options Scheme 2016, 131,881 options were outstanding, which upon exercise are convertible into equivalent number of equity shares.

5. **Exceptional items:**
   30.06.2026
   Standalone :
   During the quarter ended 30 June, 2026, the Board approved the transfer of the Company's Nebulizer brands and intellectual property portfolio to Glenmark Healthcare Limited, a wholly owned subsidiary, for a cash consideration of Rs. 2,230. The resulting impact from the transfer has been recognised and disclosed as an exceptional item in the standalone financial results for the quarter.

   31.03.2026
   Standalone and Consolidated:
   a. The Company and its subsidiary were named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S. These relate to industry-wide allegations concerning price-fixing, market allocation, and related anticompetitive conduct. Plaintiffs include putative classes of direct purchasers, end payers, and indirect purchasers of generic drugs, as well as numerous private, direct-action plaintiffs.
   Glenmark has agreed to enter into a settlement with the putative direct purchaser class and the state attorney general. The settlement is subject to approval by the court overseeing the litigation. The settlement makes clear that Glenmark denies each and everyone of its allegation against it and the settlement is not on the basis of Glenmark having considered or admitted any liability or illegality. In view of the above the Company has made a provision for the estimated settlement amount of Rs. 3,232.32 and Rs. 2,780.70 for putative direct purchaser and the state attorney general respectively and charged the same to current year Profit and loss account as an exceptional item. The matter continues to be under litigation with the other parties.

WALKER CHANDIOK & CO LLP MUMBAI

GLENMARK PHARMACEUTICALS LTD. MUMBAI

Glenmark Pharmaceuticals Limited
Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India
T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No. L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

glenmark
A new way for a new world

b. On 14 November 2025, the Company and its US Subsidiary (GPI) arrived at a settlement with United Healthcare Services, Inc. (District of Minnesota) Last En-Payor Plaintiff for a Rs 976 representing all of their claims against GPI and the Company. The settlement made clear that it is a commercial settlement and not on the basis of the Company having conceded or admitted any liability, offence, wrongdoing or illegality. In view of the above-mentioned, the Company accounted for the settlement in the Profit and loss account along with the other associated legal and other cost and has presented the same as exceptional item.
Other exceptional items primarily comprise of provision on certain inventories of Rs. 5,901, post GST 2.0 and consequent change in Inventory management model, receivables and other current assets amounting to Rs. 4,958.32, impairment of property, plant and equipments of Rs. 2,278.91 (adjusted for forex translation) and legal cost related to above litigation matters amounting to Rs. 1,394.68.

c. Effective 21 November,2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes'. The Group has assessed the financial implications of these changes and recognized Rs. 1,138.91 in the consolidated financial results and Rs. 1,130.73 in the standalone financial results towards employee benefits on the best estimate basis. The Group continues to monitor the developments pertaining to the New Labour Codes and the impact of these will be accounted in accordance with applicable accounting standards as and when these developments are known and applicable.

6. The list of subsidiaries as of 30 June 2026 is provided in Annexure A.

7. Diluted EPS has been computed considering the effect of conversion of ESOPs.

8. Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

9. The figures for the quarter ended 31 March, 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.

For and on behalf of the Board of Directors

GLENMARK PHARMACEUTICALS LTD. MUMBAI

Mumbai, 31 July 2026

Glenn Saldanha
Chairman & Managing Director

glenmark
A new way for a new world

Glenmark Pharmaceuticals Limited	
Annexure A	
List of entities included in the consolidated financial results for the quarter ended 30 June, 2026	
Sr. No	**Name of Entities**
1	Glenmark Pharmaceuticals Europe Ltd., U.K.
2	Glenmark Pharmaceuticals S.R.O.
3	Glenmark Pharmaceuticals SK, S.R.O.
4	IGI Therapeutics SA (Formerly known as Ichnos Sciences SA)
5	Glenmark Holding S.A.
6	Glenmark Pharmaceuticals SP z.o.o.
7	Glenmark Pharmaceuticals Inc.
8	Glenmark Therapeutics Inc.
9	Glenmark Farmaceutica Ltda
10	Glenmark Generics S.A
11	Glenmark Pharmaceuticals Mexico, S.A. DE C.V.
12	Glenmark Pharmaceuticals Peru SAC
13	Glenmark Pharmaceuticals Colombia SAS, Colombia
14	Glenmark Uruguay S.A.
15	Glenmark Pharmaceuticals Venezuela, C.A
16	Glenmark Dominicana SRL
17	Glenmark Pharmaceuticals Egypt S.A.E.
18	Glenmark Pharmaceuticals FZE
19	Glenmark Impex L.L.C
20	Glenmark Philippines Inc.
21	Glenmark Pharmaceuticals (Nigeria) Ltd
22	Glenmark Pharmaceuticals Malaysia Sdn Bhd
23	Glenmark Pharmaceuticals (Australia) Pty Ltd
24	Glenmark South Africa (pty) Ltd
25	Glenmark Pharmaceuticals South Africa (pty) Ltd
26	Glenmark Pharmaceuticals (Thailand) Co. Ltd
27	Glenmark Pharmaceuticals B.V.
28	Glenmark Arzneimittel GmbH - Germany
29	Glenmark Pharmaceuticals Canada Inc.
30	Glenmark Pharmaceuticals Kenya Ltd
31	Glenmark Farmaceutica S.L.U. (Formerly known as Viso Farmaceutica S.L., Spain)
32	Glenmark Specialty SA
33	Glenmark Pharmaceuticals Distribution s.r.o.
34	Glenmark Pharmaceuticals Nordic AB
35	Glenmark Ukraine LLC
36	Glenmark-Pharmaceuticals Ecuador S.A.
37	Glenmark Pharmaceuticals Singapore Pte. Ltd.
38	Ichnos Glenmark Innovation Inc. (Formerly known as Ichnos Sciences Inc.)
39	Glenmark Healthcare Limited
40	Glenmark Farmaceutica SpA
41	Glenmark Pharma S.R.L. (Formerly known as Sintesy Pharma S.R.L.)
42	Glenmark Arzenimittel GmbH - Austria
43	Glenmark Consumer Care Limited (Incorporated on 23rd May 2025)

CHANDIOK & MUMBAI

GLENMARK PHARMACEUTICALS LTD. MUMBAI

Walker Chandiok & Co LLP

42nd Floor,
Building Commerz III, International
Business Park, Oberoi Garden City,
Off Western Express Highway, Goregaon
(East),
Mumbai-400063

T +91 22 6626 2699

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Glenmark Pharmaceuticals Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **Glenmark Pharmaceuticals Limited** ('the Company') for the quarter ended **30 June 2026,** being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The review of standalone unaudited quarterly financial results for the period ended 30 June 2025 included in the Statement was carried out and reported by Suresh Surana & Associates LLP, Chartered Accountants, who has expressed unmodified conclusion vide their review report dated 14 August 2025, whose report has been furnished to us and which has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Ashish Gupta

Digitally signed by Ashish Gupta
Date: 2026.07.31 18:09:31 +05'30'

Ashish Gupta
Partner
Membership No. 504662

UDIN: 26504662KYQCVR4125

Place: Mumbai
Date: 31 July 2026

Walker Chandiok & Co LLP

42nd Floor,
Building Commerz III, International
Business Park, Oberoi Garden City,
Off Western Express Highway, Goregaon
(East),
Mumbai-400063

T +91 22 6626 2699

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Glenmark Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **Glenmark Pharmaceuticals Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries including in the Statement) for the quarter ended **30 June 2026,** being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS

34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We did not review the interim financial results of 39 subsidiaries included in the Statement, whose financial information reflects total revenues of ₹ 27,175.01 million, total net loss after tax of ₹ 868.27 million and total comprehensive income of ₹ 602.72 million, for the quarter ended on 30 June 2026, as considered in the Statement. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

   Further, of these subsidiaries, 37 subsidiaries are located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial results of such subsidiaries from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

   Our conclusion is not modified in respect of these matter with respect to our reliance on the work done by and the reports of the other auditors.

6. The review of unaudited consolidated quarterly financial results for the period ended 30 June 2025 included in the Statement was carried out and reported by Suresh Surana & Associates LLP, Chartered Accountants who have expressed unmodified conclusion vide their review report dated 14 August 2025, whose report have been furnished to us and which has been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Ashish Gupta

Digitally signed by Ashish Gupta
Date: 2026.07.31 18:08:46 +05'30'

Ashish Gupta
Partner
Membership No. 504662

UDIN: 26504662JGKRYP7767

Place: Mumbai
Date: 31 July 2026

Annexure 1

List of entities included in the Statement

List of subsidiaries (Including step down subsidiaries)

Sr. No	Name of Entities
1	Glenmark Pharmaceuticals Europe Ltd., U.K.
2	Glenmark Pharmaceuticals S.R.O.
3	Glenmark Pharmaceuticals SK, S.R.O.
4	IGI Therapeutics SA* (Formerly known as Ichnos Sciences SA)
5	Glenmark Holding S.A.
6	Glenmark Pharmaceuticals SP z.o.o.
7	Glenmark Pharmaceuticals Inc.
8	Glenmark Therapeutics Inc.
9	Glenmark Farmaceutica Ltda
10	Glenmark Generics S.A
11	Glenmark Pharmaceuticals Mexico, S.A. DE C.V.
12	Glenmark Pharmaceuticals Peru SAC
13	Glenmark Pharmaceuticals Colombia SAS, Colombia
14	Glenmark Uruguay S.A.
15	Glenmark Pharmaceuticals Venezuela, C.A
16	Glenmark Dominicana SRL
17	Glenmark Pharmaceuticals Egypt S.A.E.
18	Glenmark Pharmaceuticals FZE
19	Glenmark Impex L.L.C
20	Glenmark Philippines Inc.
21	Glenmark Pharmaceuticals (Nigeria) Ltd
22	Glenmark Pharmaceuticals Malaysia Sdn Bhd
23	Glenmark Pharmaceuticals (Australia) Pty Ltd
24	Glenmark South Africa (pty) Ltd
25	Glenmark Pharmaceuticals South Africa (pty) Ltd
26	Glenmark Pharmaceuticals (Thailand) Co. Ltd
27	Glenmark Pharmaceuticals B.V.
28	Glenmark Arzneimittel GmbH - Germany
29	Glenmark Pharmaceuticals Canada Inc.
30	Glenmark Pharmaceuticals Kenya Ltd
31	Glenmark Farmaceutica S.L.U. (Formerly known as Viso Farmaceutica S.L.U., Spain)
32	Glenmark Specialty SA
33	Glenmark Pharmaceuticals Distribution s.r.o.
34	Glenmark Pharmaceuticals Nordic AB
35	Glenmark Ukraine LLC
36	Glenmark-Pharmaceuticals Ecuador S.A.

Sr. No	Name of Entities
37	Glenmark Pharmaceuticals Singapore Pte. Ltd.
38	Ichnos Glenmark Innovation Inc. (Formerly known as Ichnos Sciences Inc.)
39	Glenmark Healthcare Limited
40	Glenmark Farmaceutica SpA
41	Sintesy Pharma S.R.L
42	Glenmark Arzenimittel GmbH - Austria
43	Glenmark Consumer Care Limited (Incorporated on 23 May 2025)

** IGI Biotherapeutics SA merged with IGI Therapeutics SA on 1 April 2025*